Gamida Cell Ltd.

Gamida Cell Ltd.

Working to turn cells into powerful therapeutics for patients with cancer.

Founded 1998

Boston, United States 93 employees Post-IPO Debt Total: $292.51M Biotechnology, Health Care +3

Gamida Cell Ltd. is a biotechnology and healthcare company based in the United States. The company's slogan, "Working to turn cells into powerful therapeutics for patients with cancer," reflects its mission to revolutionize cell therapy for cancer treatment. Founded in 1998, Gamida Cell is a pioneer in the field, leveraging its proprietary nicotinamide (NAM) technology to expand the number of cells while maintaining their intrinsic properties, thereby creating potentially curative cell therapy products and candidates. One of their significant achievements includes the approval of their stem cell transplant therapy by the US FDA in April 2023, indicating a major breakthrough in the field of cell therapy. Additionally, the company's ongoing clinical study of their NK cell therapy candidate GDA-201 shows the company's commitment to advancing innovative treatment options for cancer patients. In terms of funding, Gamida Cell recently secured a $25.00M post-IPO debt investment on 28 September 2022, with Highbridge Capital Management as the investor. This funding is a testament to the confidence of investors in the company's potential and its ability to make a significant impact in the biotechnology and healthcare industries. Overall, Gamida Cell's innovative approach to cell therapy, coupled with its recent funding success and FDA approval, positions the company as a key player in the development of advanced cancer therapeutics, offering promising opportunities for both patients and investors.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Debt	$25.00M	1	Highbridge Capital Management	28 Sep 2022
Post IPO Debt	$75.00M	1	Highbridge Capital Management	16 Feb 2021
Post IPO Equity	$60.00M	-		19 May 2020
Post IPO Equity	$35.00M	-		01 Jul 2019
Grant	$3.50M	1	Israel Innovation Authority	20 Jul 2017
Series F	$40.00M	6	Novartis, Israel Biotech Fund +4	19 Jun 2017
Grant	$4.40M	1	Israel Innovation Authority	23 May 2016
Venture Round	€2.96M	-		15 Jan 2014
Series E	$10.00M	6	Amgen Ventures, Auriga Partners +4	15 May 2012
Series D	$16.00M	5	Denali Ventures, Biomedical Investments +3	27 Sep 2006

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Debt

$25.00M

Highbridge Capital Management

28 Sep 2022

Post IPO Debt

$75.00M

Highbridge Capital Management

16 Feb 2021

Post IPO Equity

$60.00M

19 May 2020

Post IPO Equity

$35.00M

01 Jul 2019

Grant

$3.50M

Israel Innovation Authority

20 Jul 2017

Series F

$40.00M

Novartis, Israel Biotech Fund +4

19 Jun 2017

Grant

$4.40M

Israel Innovation Authority

23 May 2016

Venture Round

€2.96M

15 Jan 2014

Series E

$10.00M

Amgen Ventures, Auriga Partners +4

15 May 2012

Series D

$16.00M

Denali Ventures, Biomedical Investments +3

27 Sep 2006

FAQ About Gamida Cell Ltd.

Working to turn cells into powerful therapeutics for patients with cancer.

Gamida Cell Ltd. was founded in 1998.

Gamida Cell Ltd. is headquartered in Boston, United States.

Gamida Cell Ltd. operates in Biotechnology, Health Care, Health and Wellness, Life Sciences and Medical Devices. Its work centres on cell therapy, biopharmaceutical, NAM technology and cancer treatment.

Gamida Cell Ltd. has approximately 93 employees.

Gamida Cell Ltd. has completed 13 funding rounds, raising a total of $292.51M. The latest funding stage is Post-IPO Debt.

Top alternatives and competitors to Gamida Cell Ltd. include Jasper Therapeutics, Taiga Biotechnologies, Gracell Biotechnologies, VG Life Sciences, Cell BioEngines, Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Gamida Cell Ltd. and Jasper Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Gamida Cell Ltd.

Funding Rounds & Investors (13)

Gamida Cell Ltd. Alternatives & Competitors

FAQ About Gamida Cell Ltd.